Cervical Cancer

GlaxoSmithKline Responds To FDA On Cervarix® And Plans To Submit Final Study Data For Approval
GlaxoSmithKline provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of Cervarix®, its vaccine to prevent cervical cancer. GSK has submitted its response to questions raised by the FDA in their Complete Response Letter, received in December, 2007.